US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

710.58

+24.843.62%

Number of Gainers:84

Number of Losers:59

Number of Flat:11

PE:- -

High:710.84

Open:685.68

Low:683.13

Close:685.75

Volume:326.82M

Turnover:10.30B

Market Cap:495.36B

Float Cap:376.11B

Loading ...

CapsoVision Q2 Revenue Rises on CapsoCam Plus Capsules Sales

Acurx Net Loss Flat at $2.26 Million in Q2 2026

Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes

Tenon Medical Q2 Revenue Jumps on Higher Surgical Procedure Volume

Uruguay's DLocal Q2 Revenue Jumps 56%, Beating Estimates on TPV Growth

Veritone Q2 Revenue Misses Estimates

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

DLocal Q2 Earnings, Revenue Rise

MT Newswires Live

Caribou Biosciences Q2 FY26 GAAP Net Loss Narrows to USD 24.3 Million; Revenue Falls to USD 1.5 Million

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

ProMIS Neurosciences Q2 Net Loss Widens

Rani Therapeutics Q2 FY26 Net Loss Narrows to USD 8.42 Million; Revenue Turns to USD 1.71 Million

DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate

Benzinga Earnings

Invivyd Q2 EPS USD -0.14

Dlocal Q2 Tpv $17.70 Bln

THOMSON REUTERS

Dlocal - Updates FY Guidance: Tpv Growth 60–70%, Gross Profit 25–30%, Operating Profit 27.5–32.5% Year-over-Year

THOMSON REUTERS

Dlocal Q2 Gross Margin 32%

THOMSON REUTERS

Dlocal Q2 EPS $0.18

THOMSON REUTERS

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

THOMSON REUTERS

Rani Therapeutics Q2 Operating Expenses USD 10.536 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK4539/news?page=36"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":710.5842,"timestamp":1787687999999,"preClose":685.7458,"halted":0,"volume":326819559,"delay":0,"changeRate":0.036221,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":24.83844,"latestTime":"08-25 16:00:00 EDT","open":685.6775,"high":710.84143,"low":683.1322,"amount":10301652503.962448,"amplitude":0.040407,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.436531,"peRate":156.391987,"turnoverRate":0.025356,"increases":84,"decrements":59,"flats":8,"marketCap":495359143396.625,"floatMarketCap":376108388528.9375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":710.84143,"amplitude":0.040407,"preClose":685.7458,"low":683.1322,"pbRate":"5.436531","latestPrice":710.5842,"volume":326819559,"delay":0,"open":685.6775,"prevYearClose":881.5255,"prevWeekClose":700.9769,"prevMonthClose":673.0273,"prevQuarterClose":742.922,"fiveDayClose":655.4622,"twentyDayClose":704.4272,"sixtyDayClose":779.4826,"secType":"PLATE","market":"US","turnoverRate":0.025356,"peRate":156.391987,"marketCap":495359143396.625,"floatMarketCap":376108388528.9375,"timestamp":1787687999999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":84,"down":59,"flat":11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:36,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659167860","title":"CapsoVision Q2 Revenue Rises on CapsoCam Plus Capsules Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167860","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167860?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:17","pubTimestamp":1786652227,"startTime":"0","endTime":"0","summary":"CapsoVision Q2 revenue rises on CapsoCam Plus capsules salesOverviewUS capsule endoscopy firm's Q2 revenue rose 10% yr/yr to $3.6 mlnGross margin declined to 51% from 55% due to pricing pressure and h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4082","BK4539","CV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167881","title":"Acurx Net Loss Flat at $2.26 Million in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167881","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167881?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652216,"startTime":"0","endTime":"0","summary":"Acurx net loss flat at $2.26 million in Q2 2026Acurx posted a net loss of $2.26 million for the quarter ended June 30, 2026, little changed from a year earlier.R&D expense climbed 104% to $1.07 millio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL2cHVMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162006","title":"Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162006","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162006?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652214,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Q2 net loss widens on warrant liability changesOverviewUS biotech reported Q2 net loss widened yr/yr, driven by non-cash warrant liability changesOperating expenses for Q2 fell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A158:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4539","UNCY","ACHV","BK4139","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659028162","title":"Tenon Medical Q2 Revenue Jumps on Higher Surgical Procedure Volume","url":"https://stock-news.laohu8.com/highlight/detail?id=2659028162","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659028162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652143,"startTime":"0","endTime":"0","summary":"Tenon Medical Q2 revenue jumps on higher surgical procedure volumeOverviewUS medical device maker's Q2 revenue rose 127% yr/yr on higher surgical procedure volumeQ2 gross profit up 232% yr/yr, gross m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELA","XTNT","BK4198","BK4139","BK4539","RNXT","TNON","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162027","title":"Uruguay's DLocal Q2 Revenue Jumps 56%, Beating Estimates on TPV Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162027","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162027?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652124,"startTime":"0","endTime":"0","summary":"Uruguay's DLocal Q2 revenue jumps 56%, beating estimates on TPV growthOverviewUruguay cross-border payments platform's Q2 revenue rose 56%, beating analyst expectationsNet income for Q2 rose 28% year-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A153:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4220","BK4539","BK4585","BK4563","DLO","BK4122","BK4227","BK4588","GLBE","BK4106"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162008","title":"Veritone Q2 Revenue Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162008","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162008?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652120,"startTime":"0","endTime":"0","summary":"Veritone Q2 revenue misses estimatesOverviewEnterprise AI solutions provider's Q2 revenue rose 5% yr/yr, missing analyst expectationsCompany completed first phase of restructuring, delivering $11.3 ml","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","LU2089985449.USD","LU2931357623.SGD","DH","VERI","CBRS","LU0274383776.USD","SMWB","BK4539","BK4023","BK4167","BK4543","BK4579"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659952921","title":"Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2659952921","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659952921?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652100,"startTime":"0","endTime":"0","summary":"Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shieldingPONTE VEDRA, Fla.,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344960/0/en/cadrenal-therapeutics-reports-second-quarter-2026-financial-results-provides-a-corporate-update-on-the-cardiac-acute-critical-care-franchise-and-the-strategic-partnering-process.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","IE00B7SZL793.SGD","KD","BK4166","BK4139","IE00B19Z4B17.USD","BK4007","CACC","HIT","BK4134","BK4539","BK4173","LENZ","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659620411","title":"DLocal Q2 Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2659620411","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659620411?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:14","pubTimestamp":1786652054,"startTime":"0","endTime":"0","summary":"DLocal (DLO) reported Q2 earnings late Thursday of $0.18 per diluted share, up from $0.14 a year earlier.Analysts polled by FactSet expected $0.18.Revenue for the three months ended June 30 was $399.7 million, up from $256.5 million a year earlier.Analysts expected $366.8 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","DLO","BK4563","BK4588","BK4106","BK4585","BK4227"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659273162","title":"Caribou Biosciences Q2 FY26 GAAP Net Loss Narrows to USD 24.3 Million; Revenue Falls to USD 1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659273162","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659273162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:13","pubTimestamp":1786652037,"startTime":"0","endTime":"0","summary":"Caribou Biosciences Q2 FY26 GAAP net loss narrows to USD 24.3 million; revenue falls to USD 1.5 millionCaribou Biosciences posted a GAAP net loss of USD 24.3 million, or USD 0.24 per share, in Q2 2026.Loss narrowed from USD 54.1 million, or USD 0.58 per share, a year earlier, which included USD 21.3 million in non-cash impairment.Revenue fell 43.8% to USD 1.5 million versus Q2 2025.R&D expenses dropped 31.6% to USD 18.9 million, due to lower external CMO/CRO activity and prior workforce reduction.Cash, cash equivalents and marketable securities totaled USD 113.8 million; runway expected to extend to end-2027, with funding options explored for ANTLER-3.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLc0p1ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CRBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162218","title":"Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162218","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162218?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:12","pubTimestamp":1786651973,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences Q2 net loss widens on higher expensesOverviewUS biopharmaceutical firm's Q2 2026 revenue was zero, down from prior-year periodNet loss for Q2 widened yr/yr as operating expenses in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","CLRB","BK4563","BK4139","INBX","IMNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162415","title":"ProMIS Neurosciences Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162415","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162415?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:10","pubTimestamp":1786651823,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Q2 net loss widensOverviewUS biotechnology firm's Q2 net loss widened yr/yrCash and short-term investments rose to $53.4 mln, funding operations through 2027Company reported posit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A13R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGX","BK4539","ABOS","ANNX","BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162468","title":"Rani Therapeutics Q2 FY26 Net Loss Narrows to USD 8.42 Million; Revenue Turns to USD 1.71 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162468","media":"Reuters","labels":["shareholding","corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162468?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:10","pubTimestamp":1786651818,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Q2 FY26 net loss narrows to USD 8.42 million; revenue turns to USD 1.71 millionRani Therapeutics posted a Q2 net loss of USD 8.4 million, narrowing from USD 11.2 million a year earli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLBssyl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RANI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162939","title":"DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162939","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162939?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651584,"startTime":"0","endTime":"0","summary":"DLocal (NASDAQ:DLO) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.19 by 5.26 percent. This is a 28.57 percent increase over earnings of $0.14 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61192214/dlocal-q2-eps-0-18-misses-0-19-estimate-sales-399-664m-beat-368-858m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"DLocal Q2 EPS $0.18 Misses $0.19 Estimate, Sales $399.664M Beat $368.858M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4227","BK4539","BK4106","DLO","BK4563","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659626931","title":"Invivyd Q2 EPS USD -0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2659626931","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659626931?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651563,"startTime":"0","endTime":"0","summary":"BRIEF-Invivyd Q2 EPS USD -0.14Aug 13 (Reuters) - Invivyd Q2 net income USD -44.393 million.Q2 revenue USD 14.285 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXFW5MJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IVVD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659682162","title":"Dlocal Q2 Tpv $17.70 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2659682162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659682162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DLO","BK4539","BK4588","BK4585","BK4106","BK4227","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659621521","title":"Dlocal - Updates FY Guidance: Tpv Growth 60–70%, Gross Profit 25–30%, Operating Profit 27.5–32.5% Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2659621521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659621521?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4106","BK4585","DLO","BK4227","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659368162","title":"Dlocal Q2 Gross Margin 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659368162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659368162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4106","BK4585","DLO","BK4227","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162653","title":"Dlocal Q2 EPS $0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162653?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXKZ367X:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DLO","BK4539","BK4588","BK4585","BK4106","BK4227","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659522162","title":"Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659522162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659522162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA4MLGG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162345","title":"Rani Therapeutics Q2 Operating Expenses USD 10.536 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162345?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXRNXP6L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RANI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":54,"pageCount":36,"totalSize":1072,"code":"91000000","status":"200"}]}}